SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Reinoso M) "

Sökning: WFRF:(Reinoso M)

  • Resultat 1-5 av 5
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  • Cabrera-Rode, Eduardo, et al. (författare)
  • An Exploratory Study of Itolizumab on the Preservation of Beta Cell Function in Adults with Recent-Onset Type 1 Diabetes
  • 2022
  • Ingår i: Journal of Clinical Medicine. - : MDPI AG. - 2077-0383. ; 11:7
  • Tidskriftsartikel (refereegranskat)abstract
    • We conducted a phase I-IIa, randomized, monocentric, double-blind, placebo-controlled clinical trial to evaluate the safety and impact of the combination treatment of Itolizumab and insulin on preserving beta cell function in adults with recent-onset type 1 diabetes. Twelve patients were randomly assigned to three treatment groups, each receiving a different Itolizumab dose (0.4/0.8/1.6 mg/kg body weight, respectively) and a placebo group. All patients received concomitant intensive multiple-dose insulin therapy. Endogenous insulin secretion was assessed by the measurement of C-peptide during the mixed-meal tolerance test. No serious adverse events were reported. No changes in the total daily insulin doses, glycated hemoglobin levels, and stimulated C-peptide were observed between the Itolizumab and placebo groups at 52 weeks. A significant decrease in stimulated C-peptide was observed during the follow-up period (p = 0.012). One subject treated with 1.6 mg of Itolizumab showed a marked increase in the levels of stimulated C-peptide three years after completion of the trial. Taken together, this is the first study to demonstrate that combination treatment with Itolizumab and insulin is safe in humans and does not affect the residual function of beta cells up to 52 weeks. The findings from our study show preliminary evidence that high doses of Itolizumab could potentially arrest the loss of beta cell function in the long term. Further studies with a longer follow-up and larger numbers of patients are envisaged to assess the effect with high dose Itolizumab.
  •  
3.
  •  
4.
  •  
5.
  • Urbonaite, Sigita, et al. (författare)
  • Porosity development along the synthesis of carbon from metal carbides
  • 2008
  • Ingår i: Microporous and Mesoporous Materials. - : Elsevier BV. - 1387-1811 .- 1873-3093. ; 113:1-3, s. 14-21
  • Tidskriftsartikel (refereegranskat)abstract
    • Carbide derived carbons (CDCs) are materials containing a wide range of pore size, their properties and applications being a function of the pore structure. For this reason it is important to find the relationship between synthesis parameters, such as initial carbide and temperature, and resulting structure. In this work, CDCs were prepared from VC, TiC, WC, TaC, NbC, HfC and ZrC at different temperatures and they have been characterized by means of gas adsorption. Nitrogen at −196 °C and carbon dioxide at 0 °C adsorptions were used to obtain structural information such as apparent surface area (SBET), micropore volume (Vmicro) and pore size distribution (PSD). These studies show that these parameters vary strongly depending on synthesis temperature (700–1200 °C) and initial carbide. Since the size of micropores is near the range suggested as being ideal for methane (CH4) storage, the high-pressure methane adsorption at 25 °C was performed to check the possible use of CDCs as storage material. The CH4 adsorption capacity of CDCs can compete with other carbons on a gravimetric basis, though the volumetric one is far from desired due to their low packing density.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-5 av 5

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy